Shilpa Medicare has received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan and Armenia, for its Unit IV located at Jadcherla, Telangana, India and Unit VII located at Nacharam, Hyderabad, Telangana, India.
Both units of Shilpa Medicare (Unit IV and Unit VII) had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024. This approval will open up significant business opportunities in these countries.
Unit IV of Shilpa Medicare is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
